APG Asset Management N.V. Sells 6,339 Shares of Becton, Dickinson and Company $BDX

Key Points

• APG Asset Management N.V. reduced its stake in Becton, Dickinson and Company by 3.6%, selling 6,339 shares during the first quarter, now holding approximately 0.06% of the company valued at $36,026,000.
• Becton, Dickinson reported a quarterly EPS of $3.68, surpassing expectations, and a revenue of $5.51 billion with a year-over-year growth of 10.4%.
• The company declared a quarterly dividend of $1.04 per share, which represents a 2.1% yield and a payout ratio of 74.82%.

APG Asset Management N.V. cut its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 169,893 shares of the medical instruments supplier's stock after selling 6,339 shares during the quarter. APG Asset Management N.V. owned 0.06% of Becton, Dickinson and Company worth $36,026,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after acquiring an additional 27,581 shares during the last quarter. Foster Victor Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $6,406,000. GAMMA Investing LLC grew its holdings in shares of Becton, Dickinson and Company by 29.9% during the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after purchasing an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $224,000. Institutional investors own 86.97% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on BDX. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a report on Thursday, May 1st. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and an average target price of $211.44.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 over the last ninety days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 0.7%

Shares of NYSE:BDX traded up $1.26 during mid-day trading on Friday, hitting $192.51. The stock had a trading volume of 358,943 shares, compared to its average volume of 2,612,274. The company's 50 day moving average is $182.58 and its 200-day moving average is $194.52. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market cap of $55.18 billion, a PE ratio of 34.62, a P/E/G ratio of 1.46 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.